Background The way in which a government chooses to fi nance a health intervention can aff ect the uptake of health interventions and consequently the extent of health gains. In addition to health gains, some policies such as public fi nance can insure against catastrophic health expenditures. We aimed to evaluate the health and fi nancial risk protection benefi ts of selected interventions that could be publicly fi nanced by the government of Ethiopia.
Introduction
Protection from fi nancial risks associated with healthcare expenses is emerging as a crucial component of national health strategies in many low-income and middle-income countries. WHO's World Health Reports of 1999 and 2000 and the World Bank's Flagship course in health fi nance included provision of fi nancial risk protection as one criterion of good performance for health systems. [1] [2] [3] The reduction of these fi nancial risks is one objective of health policy devices such as universal public fi nance-full public fi nance irrespective of whether services are provided privately or publicly.
Out-of-pocket medical payments can lead to impoverishment in many countries, with households choosing from many coping strategies to manage healthrelated expenses. 4, 5 These strategies include borrowing money from peers or relatives, or selling assets to pay for their health care. A quarter of individuals in low-income and middle-income countries use these fi nancing mechanisms. 6 Without other options, such as private health insurance, household medical expenditures can often be catastrophic, 7 which is defi ned as expenditures exceeding a particular fraction of total household expenditures.
Universal public fi nance implies that the government fi nances an intervention irrespective of who is delivering or receiving it. Funds for universal public fi nance can be raised from general taxation, social insurance, external (donor) funding, or a combination of these sources. Recently, the 2010 World Health Report 8 advocated for a path to universal coverage, and identifi ed reliance on direct payments, such as user fees at the point of care, as the greatest obstacle to progress on this path. By reducing some of the fi nancial barriers to access, universal public fi nance is a key policy device for promoting universal health coverage, and it was stressed by The Lancet's e289
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Commission on Investing in Health as a key instrument for progressive universalist pathways to achieve universal health coverage. 9 Although in many high-income countries, universal public fi nance covers a wide range of necessary health services, in low-income and middleincome countries, universal public fi nance typically targets a few selected interventions in the form of an essential health package. Consequently, many health services, including preventive and curative care, require payment at the point of care. Although essential care packages have elements in common, such as basic maternal and child health services, no clear consensus has been reached regarding the interventions to be included in a benefi ts package fi nanced by universal public fi nance.
By fi nancing interventions fully, universal public fi nance increases coverage in poor population groups. 8, 10 Tradition ally, economic assessments of health interventions (cost-eff ectiveness analysis) have focused on health improvement and have estimated an intervention cost per health gain, in dollars per death averted or dollars per disability-adjusted life-year averted.
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Extended cost-eff ectiveness analysis (ECEA) [12] [13] [14] supplements traditional economic evaluation with fi nancial risk protection evaluation (ie, assessment of the number of cases of poverty averted). This analysis enables the design of benefi ts packages that quantify fi nancial risk protection and health that can be purchased for a given expenditure on specifi c interventions. In this respect, ECEA can inform discussion of some of the policy questions raised by the World Health Report 2013 15 about how to select and sequence the health services to be provided, to improve service coverage, and to increase fi nancial risk protection for households. In this Article, we apply ECEA to measure health and fi nancial risk protection benefi ts for nine interventions that could be publicly fi nanced by the Government of Ethiopia. Ethiopia has Africa's second largest population at about 92 million people, 82% of whom live in rural areas. 16 It is a low-income country with a gross domestic product (GDP) per person of about US$360, a growth rate of 7-8% per year, about 30% of its population living below the national poverty line, and a large share (roughly a third) of health expenditures fi nanced by out-of-pocket payments. 17 Recently, Ethiopia's Ministry of Health has outlined an ambitious Health Sector Development Program for 2010-15, 18 which aims to scale up coverage of key interventions, many of which we explore in this analysis. Ethiopia expects to achieve its targets in large part due to the Health Extension Program-a communitybased health services delivery programme that has helped to expand access to primary health care.
19,20

Methods
Interventions
We selected interventions that encompassed a range of health conditions, diff erent age groups (children vs adults), various incidences, and health expenditures (table 1) .
These inter ventions were among the national priorities of Ethiopia's Ministry of Health. 18 The interventions included were: measles vaccination; rotavirus vaccination; pneumococcal conjugate vaccination; diarrhoea treatment; malaria treatment; pneumonia treatment; caesarean section surgery; tuberculosis directly observed treatment short course; and treatment of hypertension. These interventions are a subset of health priorities taken from the list of interventions that the government aims to make universally accessible. 18 These specifi c ones were selected because they had the most data available and encompassed a range of conditions, ages, incidences, expenditures, and resources needed, thus showing the broad trade-off s between health and fi nancial risk protection benefi ts. Our analysis is therefore illustrative, rather than comprehensive or prescriptive.
Assumptions
We analysed the eff ects of universal public fi nancingwhereby individuals would not need to spend any money out of pocket to cover the direct medical costs-for each of the nine interventions. Full public fi nance is applied to the present coverage of the intervention plus a specifi ed (10 percentage point) increment in intervention coverage (table 1). 10 percentage points are thought to represent an achievable increment amount within a short period (ie, 1 year), in view of existing health system capacity. We acknowledge that the amount of information diff usion, implicit and explicit demand creation, and availability of services could all increase after the implementation of universal public fi nance. Generally, the expected increment would depend on various issues, including present coverage, with, for example, low and high coverage seeing lower increases (low coverage because of low access; high coverage because of diffi culties to improve further) than average coverage. We therefore explore the sensitivity of our fi ndings to the selection of diff erent incremental scenarios (5 and 20 percentage point increases).
For each intervention, we estimated both the total number of deaths averted and the total fi nancial risk protection aff orded owing to a reduction in out-of-pocket expenditures associated with treatment, per year. The amount of death and medical impoverishment prevented by public fi nancing of each intervention depends on intervention coverage, intervention eff ectiveness, and household expenditures for treatment of related diseases.
Despite some services being provided free of charge by the government (ie, essential services related to family health, control of communicable diseases, hygiene and environmental sanitation, treatment for major chronic illnesses, and health education and communication), 27 34% of health expenditure is fi nanced privately in Ethiopia. 17 This expenditure consists of direct outlays by households (including gratuities and in-kind payments) for health services. For consistency, we assume that an individual's out-of-pocket burden for treating a disease or condition before universal public fi nance is 34% of the 23 Bovet et al, 24 Elzubier, 25 and WHO 26 UPF=universal public fi nance. EPI=Expanded Programme on Immunization. *34% of adults are at high risk in ubran areas and 5% of adults are at high risk in rural areas. †60% compliance. Universal public fi nance-ie, full public fi nance-is applied to the current coverage of the intervention plus a specifi ed (10%) increment in the intervention coverage. 10% is thought to represent an achievable increment amount within a short period (ie, 1 year), in view of existing health system capacity. UPF=universal public fi nance.*Cost per vaccine dose is assumed to be US$1. †Pneumococcal deaths include pneumonia (90%), meningitis (7%), and non-pneumonia non-meningitis disease (3%). ‡By virtue of recommending smear microscopy, directly observed treatment short course focuses on the detection of smear-positive tuberculosis cases. Thus, our analysis focuses on smear-positive tuberculosis cases only. §54% of stroke incidence in people at high risk; 47% of ischaemic heart disease incidence in people at high risk. total treatment cost (direct medical cost). In other words, for the purpose of this modelling exercise, before universal public fi nance, individuals pay 34% of health-care costs and the government pays 66% of the costs. After universal public fi nance, individuals pay no health-care costs and the government pays all (100%) of them. In this modelling exercise, no other out-of-pocket direct medical costs were included (eg, costs of visits to many providers because of poor health-seeking behaviour). We use secondary data and published studies to estimate the costs of the nine specifi c interventions analysed here. All costs are expressed in 2011 US$. The number of deaths averted by each intervention is estimated on the basis of incidence and mortality data (ie, the burden attributed to the disease before universal public fi nance), intervention eff ectiveness and coverage, and the case-fatality rate (table 2) . Financial risk protection is measured by estimation of the total number of cases of poverty averted for each intervention, depending on individual income (a proxy for which can be extracted from the income distribution of Ethiopia derived from its GDP per head [$360 in current US$] and its Gini index [34] ), the national poverty line, the population targeted, disease incidence, health-care use, and out-of-pocket payments. The number of poverty cases averted is measured as the number of individuals who no longer fall below the national poverty line. 61 Specifi cally, in the population targeted, we estimate the individuals' expected income before and after universal public fi nance (depending on incidence, treatment costs, intervention coverage, and eff ectiveness), and subsequently count how many people have their expected income move up across the poverty line after the implementation of universal public fi nance.
Statistical analysis
The appendix provides full details of the mathematical derivations used for the analysis. Table 2 lists all the parameters used for the selected interventions. We used R statistical software version 3.1.0 for all analyses.
Role of the funding source
The funder of the study had no role in study design, or data collection, analysis, or interpretation. SV and all coauthors had full access to all the data in the study. SV and DTJ had fi nal responsibility for the decision to submit for publication.
Results
The total intervention costs, the extent of health gains, and fi nancial risk protection provided vary substantially across the nine interventions fi nanced through universal public fi nance (table 3) . The total number of deaths averted by the interventions per US$100 000 spent ranges from seven (for diarrhoea treatment) to 367 (for measles vaccination; fi gure). The total number of poverty cases averted varies substantially, from six (for measles vaccine) to 98 (for caesarean section) per $100 000 spent.
Measles and pneumococcal conjugate vaccinations are the two interventions that prevent the highest number of deaths per $100 000 spent, since the measles vaccine averts 367 deaths and pneumococcal conjugate vaccine 170 deaths. The measles vaccine is very eff ective (85% effi cacy), is quite inexpensive (US$1·0 per child), and the disease is highly fatal (3·5% case-fatality rate). By contrast, diarrhoea treatment prevents the smallest number of deaths per $100 000 spent (roughly seven), since the intervention is not so cheap (US$6 for outpatient visits and $34 for inpatient visits) and diarrhoea is rarely fatal (0·15% case-fatality rate). Similarly, treatment of hypertension averts only 11 deaths per $100 000 spent, partly because of the low estimated incidence of stroke and ischaemic heart disease (<100 per 100 000 population) and the low eff ectiveness of this treatment (39% eff ective 
The numbers in parentheses are the ranking of each intervention in deaths averted per dollar spent and poverty cases averted per dollar spent. at preventing stroke and 30% eff ective at preventing ischaemic heart disease). Conversely, caesarean section averts the highest number of poverty cases (98 cases averted) because the associated out-of-pocket costs are large (US$30-70) and the number of pregnant women in need of caesarean section is substantial (around eight per 1000 pregnant women). Similarly, tuberculosis treatment and hypertension treatment lead to the second and third highest number of poverty cases averted (96 and 84 poverty cases averted, respectively), since they also create substantial out-ofpocket payments (US$65-90). Measles vaccination averts the smallest number of poverty cases (six), since the out-ofpocket payments by the benefi ciary are small ($5 for inpatient visits and $0·50 for outpatient visits). Overall, adult treatment interventions (tuberculosis treatment, caesarean section, and hypertension treatment) provide the greatest fi nancial risk protection. The vaccine interventions (measles, rotavirus, and pneumococcal conjugate vaccines) produce less fi nancial risk protection (per dollar spent) than the childhood treatment interventions (treatment for malaria, diarrhoea, and pneumonia). In particular, one potential approach for subsequent interpretation could be to infer a trend line (fi gure) highlighting substitution between health and fi nancial risk protection benefi ts: for example, a linear approximation (R²=0·61) points to a reduction of about two poverty cases averted per additional ten deaths averted. Trade-off s inferred from such a trend line or from a frontier (ie, the line joining the caesarean section and measles immunisation points [not shown]) can prove highly sensitive to the interventions included. For example, if the measles vaccine were excluded, the R² would be reduced to 0·29.
Finally, we assessed the sensitivity of our fi ndings with respect to a change in coverage increment (5% or 20%; table 4). For the vaccines, when coverage increment changes, health and fi nancial risk protection benefi ts per dollar spent are maintained. For all the other interventions, when coverage increment decreases (to 5%), per dollar spent, fi nancial risk protection benefi ts increase and health benefi ts decrease; conversely, when coverage increases (to 20%), per dollar spent, fi nancial risk protection benefi ts decrease and health benefi ts increase.
Discussion
We present results for an ECEA of universal public fi nancing of nine health interventions in Ethiopia. In particular, our approach assesses the consequences of universal public fi nance in protecting families against fi nancial impoverishment, in addition to the dimension of health gains. This type of analysis is not possible with a traditional cost-eff ectiveness analysis, and emphasises potential trade-off s for policy makers as they choose between alternative pathways to universal health coverage (panel).
The introduction of universal public fi nance for key interventions could bring major fi nancial risk protection benefi ts in addition to substantial health gains. Our fi ndings align well with several expectations. First, if we assess health gains per dollar spent, the results fall within the range of previously reported cost-eff ectiveness analysis estimates. 11 Second, the conditions with large out-of-pocket payments are associated with high fi nancial risk protection, and low-cost interventions (eg, treatment for hypertension) can lead to large poverty alleviation benefi ts. In addition to cost-eff ective interventions for which effi cient purchase of health gains is realised (eg, the measles vaccine), there are so-called fi nancial risk protection-cost-eff ective interventions for which effi cient purchase of fi nancial risk protection benefi ts is realised (eg, hypertension treatment).
Although ECEA is neutral with respect to what ought to be prioritised and included in a benefi ts package, the method allows policy makers to take both health and fi nancial risk protection into account when making decisions. Consequently, scarce health-care resources could be more eff ectively targeted in accordance with specifi c policy objectives. For example, although potentially discarded on the grounds of health benefi ts, hypertension treatment might be included in a benefi ts package based on fi nancial risk protection benefi ts. Similarly, based on our calculations, public fi nancing of a 
5% increase in coverage
Rotavirus vaccine 400 000 90 000 250 (3) 140 (7) Pneumococcal conjugate vaccine 600 000 55 000 840 (2) 80 (8) Measles vaccine 130 000 5000 450 (1) 10 (9) Diarrhoea treatment 38 000 000 26 000 000 1800 (9) 40 000 (4) Pneumonia treatment 23 000 000 15 000 000 2000 (7) 23 000 (5) Malaria treatment 480 000 300 000 210 (5) 460 (6) Caesarean section surgery 340 000 266 000 290 (4) 410 (1) Tuberculosis treatment 5 600 000 4 400 000 1300 (6) 6700 (2) Hypertension treatment 1 000 000 730 000 70 (8) 1100 (3)
20% increase in coverage
Rotavirus vaccine 1 600 000 350 000 1000 (4) 540 (4) Pneumococcal conjugate vaccine 2 400 000 220 000 3300 (3) 340 (8) Measles vaccine 520 000 19 000 1800 (1) 30 (9) Diarrhoea treatment 75 000 000 26 000 000 7200 (9) 40 000 (5) Pneumonia treatment 47 000 000 15 000 000 8100 (7) 23 000 (6) Malaria treatment 1 030 000 300 000 820 (5) 460 (7) Caesarean section surgery 570 000 270 000 1200 (2) 410 (1) Tuberculosis treatment 9 500 000 4 400 000 5200 (6) 6700 (2) Hypertension treatment 2 000 000 730 000 280 (8) 1200 (3) The numbers in parentheses are the ranking of each intervention in deaths averted per dollar spent and poverty cases averted per dollar spent. 10% increase in tuberculosis treatment and a 10% increase in malaria treatment would provide similar health benefi ts per dollar spent. However, tuberculosis treatment provides substantially more fi nancial risk protection than malaria treatment and therefore is likely to be the better investment until resources are available for both. This analysis also provides policy makers with information about how they might sequence the development of health-care packages as the health and fi nancial needs of populations evolve and resource envelopes change. Finally, health policies can be compared with policies from other sectors aimed at poverty reduction (eg, education, transportation, and development). Our analysis has some limitations. Most importantly, with respect to our Ethiopian case study, we studied a small number of Ethiopia's health priorities. 18 This selection was largely because of scarce data availability, with nonetheless the intent to include a range of conditions, ages, incidences, expenditures, and resources needed across interventions, so as to illustrate broad health-fi nancial risk protection trade-off s. The analysis is therefore illustrative: it is neither comprehensive nor prescriptive. Specifi cally, through its Health Extension Program, 19, 20, 62 Ethiopia has introduced community-based primary health care. The programme proposes 17 packages of basic services in four subdomains: disease prevention and control; family health; hygiene and environmental sanitation; and health education and communication. Every community builds a health post; two health extension workers from the community are trained to provide households with disease prevention advice, accessible services at health posts, and referrals to health centres. 19 Therefore, a detailed case study should represent this comprehensive design; our analysis presents a selective primary health-care view, largely because of low data availability and our aim to be illustrative. Thus, several key interventions from these subdomains, including prevention of mother-to-child transmission of HIV, family planning and reproductive health, and treatment of neglected tropical diseases, were not included.
Similarly, integration of services including reduced costs through economies of scope and synergistic eff ects rather than single interventions was not considered. Therefore, the selection of an optimum bundle of existing and new packages for the Health Extension Program, with comprehensive assessment of opportunity costs, health, and fi nancial risk protection benefi ts remains to be done in future work. Importantly, in doing so, one should learn from other low-income and middle-income countries that have introduced publicly funded services towards universal health coverage. 63 For example, Rwanda's experience suggests that mutual health insurance increased healthcare use and fi nancial risk protection. 64 Through its Health Transformation Program, Turkey substantially enhanced equity with an improved level and distribution of health, more fairness in fi nancing, and insurance coverage rising from 2 to 10 million people within 10 years. 65 In another example, Thailand's health reforms increased insurance coverage and signifi cantly reduced child mortality in the poorest groups. 66 Second, ECEA is only one method for priority setting. In addition to cost-eff ectiveness analysis or ECEA, decisionmaking should also include other ethical, social, political, and economic considerations, such as benefi t to cost ratios; 9 the strengths and weaknesses of the host health systems; and use several criteria including those related to disease (eg, severity), targeting only specifi c individuals (eg, high-risk individuals) rather than a wider group of individuals, and other non-health consequences (eg, education). 67, 68 By introducing ECEA, we intend to address some of these well understood limits of cost-eff ectiveness analysis 69 such as fi nancial risk protection (one important dimension of universal health coverage), but much remains to be done in addressing how to improve these extensions and to deal with the concerns about costeff ectiveness analysis that ECEA does not yet address. Unlike most other ECEAs, [12] [13] [14] in this report, we did not disaggregate results by income quintile and did not directly address the issue of equity. If a government were to prioritise interventions, there would be equity implications and the need for disaggregated analyses. We focused on fi nancial risk protection because of scarce data and to be parsimonious in adding dimensions to health benefi ts.
Third, as is the case with many published costeff ectiveness analyses, our disease models are static [12] [13] [14] supplements traditional economic evaluation with estimation of fi nancial risk protection provided by health fi nancing policies. Universal public fi nance is unique in that the government fi nances an intervention irrespective of who is delivering or receiving it. By contrast, although much has been written about the impoverishing eff ect of health expenditures, little attention has been paid to how public resources can be used effi ciently to protect against this risk. In this Article, we apply ECEA to measure both health and fi nancial risk protection benefi ts for a bundle of nine (among many other) interventions to be universally publicly fi nanced by the Government of Ethiopia.
Interpretation
Our approach incorporates fi nancial risk protection into the economic evaluation of health policy. This step allows policy makers to establish how much fi nancial risk protection is being purchased with a given benefi ts package, in addition to the assessment of health that is being bought with incremental increases in public spending. The approach can inform the design of essential health packages on the pathway to universal health coverage.
rather than dynamic. Compared with static models, dynamic models can more accurately capture synergies but also have a bigger reliance on additional data and assumptions about disease behaviour. The inclusion of the number of secondary cases prevented would lead to increased numbers of deaths and poverty cases averted (for example, an increase to 41 deaths averted and 97 poverty cases averted per $100 000 spent for tuberculosis treatment). Additionally, the longer term benefi ts of vaccination in those older than 5 years of age were neglected because the burden of disease is largely concentrated in children younger than 5 years of age.
Fourth, a more comprehensive accounting of household medical payments could be done, including payments caused by poor health-seeking behaviour and visits from many health-care providers. In particular, direct nonmedical costs (eg, transportation and housing costs) and indirect costs caused by the disease or condition, including loss of earnings and eff ect on labour productivity, can be substantial. Fifth, scarce data about the existing mix of public and private provision and purchase of health care aff ected our choice of interventions. Sixth, we did not do a full uncertainty analysis but rather included a sensitivity analysis, since the purpose of this report is to expose with simplicity a methodological framework for policy makers, and not to provide them with defi nitive estimates. Finally, we chose to represent fi nancial risk protection in terms of poverty cases averted. Alternatives include a money-metric value of insurance wherein a utility-based framework is used and in which individuals seek to avoid uncertainty, 12 and avoid cases of forced borrowing or sales. 6 We chose the metric of poverty cases averted because of both data availability and simplicity. However, the use of this metric has associated issues-namely, the choice of a poverty threshold and the fact that individuals living below the poverty line might not always be accounted for. 7 Similarly, we relied heavily on secondary data and published studies to estimate eff ect and costs. Moreover, the health metric of deaths averted was retained for simplicity and ease of communication, which could introduce bias towards high-mortality diseases, and could be replaced by a constructed metric capturing both morbidity and mortality such as the disability-adjusted life-year.
Future studies will expand on this analysis by incorporating other essential features that promote realism of the scenario. For example, fi nancial barriers are not the only barriers that prevent individuals from seeking care: absence of information, low availability of services, and long distances to health-care facilities are also important. In countries with a low density of health workers and weak health infrastructure, such as Ethiopia, health services might not be available even after some of the fi nancial barriers are removed. In particular, expansion of health services to rural areas might need additional investments, such as strengthening of health facilities through training and deployment of skilled health workers, provision of essential equipment, and infrastructural improvement for service delivery.
Acceptability issues related to culture or quality also exist. Universal health coverage does not necessarily ensure quality, but innovations, such as accreditation to participate in universal health coverage schemes 70 instituting basic quality expectations or pay for performance schemes, can improve quality. In turn, these barriers will limit expansion in the amount of coverage initially achievable by universal public fi nance. To address this situation, we chose a specifi ed coverage increment of 10% for all interventions. However, the expected increment would depend on various issues, including present coverage, which is why we included a sensitivity analysis. Moreover, marginal costs of health-care provision might increase substantially with coverage increase, and these marginal costs can vary depending on the population subgroups targeted (eg, diff erent education or socioeconomic groups). Similarly, signifi cant diff erences exist in disease incidence or mortality, and health-care use, which vary by population subgroups. For example, poorer children are more likely to die from rotavirus than are those from wealthier families, and richer children are more likely than poor children to be taken to health facilities when they are ill. 13 Finally, ECEA can be applied to the evaluation of other policy devices besides universal public fi nance, including prepayment mechanisms (eg, who should fi nancially contribute and in which way), conditional cash transfers, or fi nancial incentives.
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